We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Company To Promote and Commercialize bioMerieux Range in Japan

By HospiMedica staff writers
Posted on 22 Jan 2008
Print article
Sysmex Corp. (Kobe, Japan; www.sysmex.com) and bioMerieux (Marcy l'Etoile, France; www.biomerieux.com) have signed an agreement to form a new company called Sysmex bioMerieux, Ltd. The company will promote and commercialize the entire bioMerieux product range in Japan.

bioMerieux has been operating in the Japanese clinical diagnostics and industrial testing market through bioMerieux Japan, Ltd., a fully owned subsidiary. The joint venture (JV) will manage the regulatory filing and marketing activities of bioMerieux product ranges in Japan. The sales and customer service activities will be contracted out from the JV to Sysmex.

Sysmex and bioMerieux have been developing their global partnership since July 2007, when bioMerieux became a global partner to distribute Sysmex's highly standardized and automated UF-1000i urine sediment analyzer to their extensive clinical microbiology customer base.

bioMérieux provides diagnostic products (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical, and cosmetic products.

Sysmex performs clinical laboratory testing of blood, urine, and other specimens, providing instruments and reagents for clinical laboratory testing as well as laboratory information systems. The company, which specialized in hematology, has expanded to offer a comprehensive range of diagnostics products and solutions in the diagnostics field including coagulation, biochemistry, immunochemistry, urinalysis, and other disciplines.

The market volume of microbiology testing in Japan is estimated at approximately US$280 million per year and is regarded as a strategically important market, the second largest in size worldwide.


Related Links:
Sysmex Corporation
bioMerieux
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Automated Blood Typing System
IH-500 NEXT
New
Human Insulin CLIA
Human Insulin CLIA Kit
New
Automatic Biochemistry Analyzer
Audmax 180 Evolution

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.